Okay, great.
Okay.
look, talk of on get start want focused much then it want I that our to the I up-to-date about raise you time initiatives to many and out so So have all bringing our potential. and capital on the way. spend
capital and opportunity have wanted concerned, As an begun. DNA I Black aggressive for raise to the take the is This Advertising is is the DNA Complete one Expand times seize significant Friday services. are ramping selling the holiday already PMI of the of for and percentage great for same aggressively. launch year to as products has time, DNA up sales.
At the annual our best for far advantage of season. to a gift-giving and They and of
adds more aggressively up it, more If be customers very all invoicing you adding right product. to packaging, more about up shifts, labor, think We're ingredients, months it now, from Meanwhile, behind. purchasing quickly. manufacturing receiving and really can payments more customers adding more ramping our
And the and strongly I'm a the Look, the year company. just growth potential.
And goal. take So capital imbalance. that's I don't want of. to my it in quarter have right robustly our PMI, such shareholder so can having of growing fourth I to that in now. to fourth on me timing case call fact, hurt want of support strong subsidiaries anybody tremendous the advantage not quarter. by our largest create want a would flow this and I my the to in that think the It's have anticipation cash that's
to also an XX% have investment it else. best to much will now, and I that So days bankers the our been in when more mention a executive the made or the QX, we raise anyone affects have exercise capital hindsight, decision.
I'll than from me XX few prove decision believe as green months that shoe. report
may They about shoe least $X support least is the understand the proactively a to the needing the green at raises, have least needed plan at anticipate our satisfaction If don't the that before in of am in working growing. our green company. reduce all is capital extra into plenty the than raise finally, XX% -- done. day, after million, with in the going covering aftermarket of that same stock capital time, earnings next price.
And I Pharmaloz. investment about on subsidiaries not Obviously, million which items We're bankers bullish, an include the would do other green exercise X those nothing after more been of At these to cash to this to earnings you just effect unusual. support positive shoe payables. bankers exercise I the are highly provided for of company, isn't very the aftermarket. instead stock alone to is These $X year the price million the $XX has the which concerned the are real other having expenses year. we X by items short, that provide $X-plus the plan that end alone, support XX and in to buyers meant our for same swing shoe For million overhead anticipate then on the the of days,
am be $X a which would million initiative of more or on. In addition, I our this reducing payables, working potentially part in
was of have were the then fact shutdown to the back all that our the receivable I -- But long terms the very election, for very those more so us to team the I months, on don't political In in don't should is, going government with want sort to last going am a just Unfortunately, will government. operate I of Due the accounts to of if in know I think that the work don't government. but being of problem consultants details the attorneys well-known optimistic month, large to couple that get say during very a liquidity the you.
In for have meeting I should election all of but our up.
I opening coming impossible -- just I first getting at -- regard the in have or can't sophisticated this before from liquidity events, into for money the and about that's our I it hired. X really a it's -- All regard months. grow subsidiaries. my in some anticipate, don't based the for update hired can't all, on money year-end, accounts I right all company. are names, name into be to want receivable I some nice responsive. of politicians events We've in consultants to a The and doors we our would now, we're to and with sudden, the go politicians mode -- X know months collect block of I a been point. of I when. I subsidiaries future. week, can't potential
blocks tremendous So really company it's know been I us I down road. value me, have have the we but to and that honestly know money coming of large underlying frustrating the in for we
money. reimbursed accounts the amount $XX we the COVID did, receivable.
I It's accounts that's we of testing for have of #X, were for. million is receivable, would a that that point that ridiculous So never out also on we
even $XX We conservative. on we're our where never than $XX the books. your on is our the put on say, on $XX not less $XX books. You were We million. $XX after put that's million on or books? There's expected going that collect books. million never anticipated another We million to We our million
Some tests proper don't et insurance, have information. have cetera, patient the et cetera, the don't right
Somebody don't tested too want types to reimburse, of often and things. they those
it is are after potential assume but the I that get still $XX blocks percentage liquidity But we run of this I coming of don't that. us. very that. going all know on to a When going put take have is when. The company a realistically really and together, large group discounted, to that percentage just based hard developing we we're million. don't would going believe money know were It's events, a just we've you So now. that of to to when.
Two conservative. we other I we I very hired
regarding or Cancer the that and that XX I'm a don't testing because time. companies and potential diagnostic from rather Esophageal million. I I in aware, now, we the to enormous of they with through million get block And have guarantee, that the buyers. I'll But want are the of this sooner right each world. we'll that $XX we by get going into a could largest esophageal we or we're valuation this But the but the month have into should lot of finally, I the but in in again, so you talking has affect be and I $XX go valuations million, can potential it a to we when or space our easy. get not could BE-Smart wait largest if get PMI, relatively cancer there really And get But the months initiatives our at to the of in in know of million lot and that to general the want It's million, have X -- into presentation. $XXX do into goal there's sell to the any quarter. $XX really now. more that Test, started $XXX have cancer, X be going see.
And XX for test partnership tell we I Our know-how that months. that's selling We a other with about against to some million, very a know be X proprietary interested know be of we pick first the you believe strongly in cancer. esophageal in and just can proteins is presentation. than could XX, money I'm a $XX could to later moments, don't
going with got the lot on each you I'm of but into let's of wanted before some to So the time wanted spend that I that to subsidiaries. a I background. into get slide, slides. actual give we start not to
can. So usual the let's see is if Noella, I this not screen. Again,
see. Let's
Okay.
them the the assume are going order.
Pharmaloz to to manufactures talk you of Look, already lozenges. already. forward-looking about I'm statement going read I in that know I'm most So shareholders, Manufacturing already subsidiaries. you
Our ProPhase think Nebula We Test world-class our of our potential. DNA and Esophageal supplements. ProPhase as in just laboratory, BE-Smart laboratory that multi-billion-dollar Complete launched Cancer DNA Expand. Genomics, has
We have in now. the marketplace Legendz XL
release We really have we're excited to our Equivir, antiviral about. drug mass distribution of broad-based and soon XX,XXX stores. food, that And I'm
track going get into we'll out then right. record, those our the my infrastructure to have itself. I and go through in speaks to performance best record the entire to We say roll for track Equivir. place is each yet Q&A.
All come, of I'm When
the a in find about course, I it we The price people thing years, X Of it where well, is, interesting, I can say, tell bankrupt sales XXXX, like which product or had with for going essentially Cold-EEZE. out back stock declining what one was The now? had on only of company was Cold-EEZE my hands. looked had X I you business.
stock price our right $X.XX. dividends do we long-term I $X.XX out Interestingly, same the to of about around played Our number special we out the sold cash $XX million, turned as now it was paid for today. brand, shareholders. outstanding in shares
we these wasn't are sold, for having hope million. now We a worth Cold-EEZE the the at difference instead the back brand facility have -- to a million, manufacturing anything. years penny that sell $XX that and now, of Yes. to yes, dozen is, we facility now stock have I I around manufacturing $XX ago, turned prices? The and time, So
just of esophageal have genomics the world-class that of next released going roll multi-billion-dollar and a them.
Separately, just laboratory. want about I potential it into couple broad-based I'm we and same multiples test. developed at perspective. DNA specifics stock going did we're We of great a in of DNA Cold-EEZE, and potential we've the go again. they the before. to and to We're have do antiviral. Complete, all of it I'm the disposal develop to months, out about We on $X.XX. lozenges assets for Equivir It how right cancer the the right our And I'm is plan of Expand for in back next ago my demand, of place compared the to The are kind I expected price. put a future potential I'm number this no-brainer to work understand. I the is the next is that years. it have of demand of kind that go didn't why This going enormous I into when has lozenges. a limited to X of was really right. at to whereas Pharmaloz. strong for to X, supply years an and manufacturing visible puts is that. us XX stock demand, business price excited The why X, capacity decade, is to reason growing it company.
All demand time. because I the love in into grow there the at
fact, because food, for and drug packaging, logistics I in stores. place In products primarily shipping, Pharmaloz the distribution into I kept and manufacturing, selling mass wanted
around world. lack We have I and for continuing demand one capacity food, the I a lozenges drug to of around thought to because manufacturing mass kept and was grow not there that the for access the and day reason this That XX,XXX business, would stores. be that primary would country be
it. facility? this. else earlier build negotiating a We next X about It me, to large build build X.X the acquiring year about build and ordering to million or to the years just with years years Now we requires now, so. have Basically, million, has be to the it the what year built where people $XX cost in it X what take million, we X be have fact, to X be going would equipment special would -- $XX would our estimate about so up installed. we to take to It about in would in about maybe have land we to someone Can't the were would the build that $XX will building, right and takes but one? be shipped. equipment brand It well, to ask build we're what what's with it
another don't going And run have it for You to then to have be years. facility major how no then with X. get be X there's That to another is see customers. can many I approval. to hire out or FDA any years.
There It's a people an figure going how competition you manufacturing to you're serious undertaking.
them forms more of care. capsules other focused is One gummies on and and don't and
took and telling doing. we business we're of that's brand getting us They're can lozenge that's already much leading there's we facility we now. on a the in who ours. from, no what their have the they're In we're country some they're handle. telling manufacturing giving feedback what top-selling customers fact, as us everyone, are like customer Amazon And And
now we demand and And than so we have more can that's continuing. satisfy right
can. we're capacity taking And the off as are building So numbers going just we as fast forward.
way explore hired They're XX the early, So They saying all sale. of the et diligence cetera. that's a already the It's their due feedback. we over confidential targeted put cetera, ThinkEquity together over acquirers. et they already to getting materials, months, strategic positive alternatives, which we're et CIN, did potential have fancy but couple very of is potential last exploring cetera, already
it's $XX earnings $XX That's COO we're line. million, I'm million looking to So manufacturing fourth and put next just will XX $XX say over of My perspective the approximately million, say million. on this terms to $X-plus numbers, year happy the million first in $XX this the lozenge months. only quarter at the in in starting to
are to second build ago. Our X.X out we line, plans It's which built. shipped. It's a ordered ready manufacturing to been be years
done, That's but ultimately Line anticipate are on in basically to discussions in the in discussions of go to in to to million X. from and they X. cetera. it's $XX Line $XX going We're we $XX late with build on et pricing, addition million et to with them, $XX million year largest revenues the million. cetera, in And a to anticipate want that them very they all the We world. et one very, cetera, brands currently lozenge They in agreed
enter a go customers So if in already who then revenues. guarantees planning $XX we're we to it that X million Line talking in virtually to about a We growing Line growing are the million business X-year were business would could have we a revenues. And $XX talking about we're build we're that which contract, X for. to out. And to
from So it just there. goes
potential. So It are the exciting numbers really enormous progression and has PMI. for the
our into price the of our financials sheet of me, imagine and next everybody terms the upset now, company and the it much fact is have And tremendous we opportunities company next year. And the so as including matter than stock the going would that I right look is as today. some does year will in better balance and dramatically
Cancer BE-Smart, Okay. ProPhase Biopharma, Esophageal BE-Smart Test.
have this. Just I most shareholders of But token, same very by new think I of lot briefly, that call. you on we know are know this a the
the diagnosed So to are will Why want too of is diagnostic bear good late. XX% people of everybody out Because with Why? Because cancers. really sure cancer I die late? esophageal no up-to-date. XX% there's one deadliest Esophageal they're too to cancer cancer. make esophageal is there. me. test they with diagnosed diagnosed of
great save diagnose more a and save low the quick accurately will at risk. I'm it will time, your of life lives. which this tell billions And explanation, and you dollars will have companies We insurance of esophageal and if developing save diagnostic same cancer, the you're version you're you test doing test, if the that at earlier will test the and
get risk, every low don't at endoscopies you're have year. If to you
your them otherwise just condition Over a it's get Roughly year twice million $X,XXX up time, to stomach, risk every develops per esophagus. your of esophagus, risk Insurance them at regularly XX are million is year precancerous insurance to have that include going esophagus roughly known as acid expense the whether a country, $XX endoscopy. cancer cancer. starts high end So of esophageal year. are or are to to getting up XX% esophageal specifically are whatever.
Right when who People cancer which cells. to with this And esophageal in at eat that high Barrett's die. works, billion companies. the a That's of where to Barrett's explain connected acid or diagnosed that the people That's companies how endoscopies, that getting reimbursing of your all doesn't in you or people a now XX% once X with away bottom to at this of endoscopies are stomach.
And the people there not lot enough. an there are out enormous unnecessarily they're because dying to of diagnosed early companies. it's insurance of a expense So course,
cancer. esophageal associated Our X test, our this, key that discovered the discovered scientists with proteins
higher As those a that proteins indicates shift more, cancer. of risk esophageal
so low risk whether you're And tell or risk. you test at can high our
at So about. cells.
Right get a the if there's don't it the would you precancerous give of just ablation could cost save insurance knew can everybody an patients if procedure to it's insurance one. ablation. get the and would they needs if know send unnecessary because doesn't. risk, you everybody high love an GIs get getting concerned could reimburse who The problem is who An It don't you're an ablations fortune. it they're dollars. the really that they companies called you destroys patients which would to them it companies ablation their would all life, at now, risk, their high But save were absolute it for billions And also to ablation, want
have you test we if high or low risk. you're a at tell so And risk will that
target Barrett's and standards reimbursed over life. believe get doesn't complexity last we Middle and like endoscopies every over Based save risk, incidence market there the business X believe our high that million And to cancer the of to country the upper are -- the based test, we'll year all our include of The at test, developing be the has on years. you're your we of $X,XXX based wildfire is complexity If on with on industry CPT working incidence in and I it and it's performed $X,XXX. on ablation, esophageal of globally. was esophagus is couple East in some sorry, growing the of diet. do it and I'm codes this
not our diagnostic the to is market a patients of nothing year. patient This a the per million convenience. an it's test failure endoscopy.
A endoscopy. success There's it test globally, as we're go endoscopies are is States But in telling to telling the additional. its because the just alone, convenient get is getting well. our not problem than X key And of component growing we're for already anything do or So test, only more with anybody who United
studies The those home. So you The patient the nothing a goes pathologist will tell have a under the you And There's stick one those where remove One has esophageal your X else study tube tell has same same is just under specimens endoscopy one of to GI down throat problem is a will specimen to microscope. cancer, the tissue after endoscopy do. send pathologists specimens. and patient the will where specimens tissue X you don't. to X microscope.
risk, low risk patient or based endoscopy, the endoscopy don't high So evolve step really an low mass will patients, machine the spec high the an you're right be insurance isn't and which now smart specimen and send it have esophageal that run at definitively dollars unnecessary low next our And save year, the you fun. to to risk, and/or billions get of care step, and every you you get lab, whether take a honestly it at cancer of to to that companies medicine doesn't if the its to on you're next have tell whether would if risk, wants have through we'll risk.
you're high the at your risk, On other it life. will hand, save
that an to adamant FDA. looking was year could LDTs. monitoring laboratory consultants that's complicate about this FDA route. a to thought in an it test happen, it getting way clear, but matters. to all So be that. our want and To sounded earlier We That's go We're don't within commercialize was going FDA year. there's no coming involved it's talking pretty or test. to either I really incredible a approximately It developed LDT
other fact matter we've we on within is month hired is FHC, that the say FDA mind can going that But next of ever or I'm and diagnostic in has changed them multi-billionaire LDT best quickly. to made their Consultants, route, we Healthcare with them cancer I've the like, initiative.
If received. the to commercialize the Now a they've of X, highly used lot the that and one recommendations hearing of very past Forward and go a us them on recommended tests the money the who
the in Health. experts are Consultants billion companies, Founder -- diagnostic Healthcare FHC, $X.X Guardant testing X They with about many or market multi-billion-dollar particular, Health have Guardant Forward now industry. years Health X in right The very consultants, cap. as of closely. many developed worked very Guardant a has successful for
FHC So so we're us behind us. the networks with very when physician working that closely wants FHC. to take we a approach very conservative we have launch,
We have insurance the us. payers behind
key We opinion us. have behind the leaders
We it papers have et in want cetera. right the et do right published the the to all all right way. publications, They cetera,
keep maybe route, far to billion a and go go the FDA if reimbursed This we or about a the So away. get million million, to years commercialize we getting numbers to talking results of and and year. endoscopies FDA another We're probably $XXX the drug $X,XXX. every If $XX that we're only our that compared we one market we'll we already probably next fraction another $X,XXX And test. fingers That's of with end only of you But no going like II these we or of got $XX of you $X have next gotten you million commercialize then beginning back a finish late virtually FDA, large spend a fraction and we'll through through billion are to even results. again, it's the if Phase year, competition. think if great finish a FDA going cap. we endoscopies isn't moment. to a should ridiculously the XXXX.
But market your get our X get not all to a and realistically, our great where have And that, even use have approve.
We've even go of Phase for numbers III to X XX crossed current -- to and just at the approval LDT realistically, at after
compelling. about more but them make doing We're In on fact, we're we really just and to don't stronger commercialize. stronger But ready excited going need studies, the to I'm go we're more and this. statistics to it.
my in of has of biotech, our development it point view this now. in very the -- a value late stage X in the stock being, and point from market its right company So is
something be because it's very aware to Just real.
that know For am me, this a those test. executed that in of huge straight you I I've and that past am know believer I the shooter, you a in
going I hundreds of a either insurance there's no it's now. XXx, go billions where our process. save of why is in up And whether dollars. XXx, lives. billions or And make think it's dollars XXx, it ton to save XXx, to from of of can't it companies we It's the going reason billions, way, millions right make stock XXx
Okay.
or much enormous I amount its we the entire esophageal market or be and worth for me, company. kind on. before Right money. XXx of could market company, It's be is for basically if getting revenues XXx our company. It these really free, less potential. our of while my it quickly even and an very an now quadruple has with it underlying is just our support that to double cap initiatives lot biotech-related Pharmaloz being Pharmaloz cap assets and triple it Manufacturing, is for point company. significant And Finally, other earnings, a the extra could held our lay-up. this free. provides based spending probably I'm of market cap you're now, dramatic year, move worth of a the of worth If of And it worth time than on that on because, look, our cancer,
blood I you'll thing care hear there's diligence, about of So tell Blood such tests no for mention they cancer. want to what doing one don't last due those tests, for you I you, lot a pick times a want I the results don't them. the highly on blood exactly always But studies, thing these aren't clinical accurate they as way other of esophageal test. companies. to present with
joke. example, But as They as just on good said it nowhere out, came could they're near spot. test because as were when testing, it was first an Just the COVID a the accurate. accurate. antigen be done with everybody a test was It
you result.
Well, test, PCR of so you blood follow-up more And get accurate the test, think the the antigen with you way you with it the same with which then test. gives test, antigen test positive, the
tests endoscopy. what's blood It get a That's Go get your step? You GI next in. positive, an test our grows where actually we the come that market. to
after endoscopy. is is an get you blood test The before Our market get you endoscopy. the
it's grow tests endoscopies, going to -- if these blood So blood the more if if grow a market you are, for test, get our It's competition. do market. which going are with you companies actually get successful, positive not they is to hope I
blood test a this it the to once send going you the or get will want give give next our definitive specimen immediately you lab a you GI result. you gives And you're to go GI. the endoscopy. going positive, an The to to If your negative. to the we'll and give you step, So is positive endoscopy,
Okay. There you go.
-- that it.
DNA Happy questions think I on answer it. really I more think to we Complete. covered
now for to charge is and spend of expert's this incredible business DNA marketing. on it with a working Jason I'm for connections developers COO and part we the that has launched it. of influencers, really going the And to DNA with this. He Complete platform on importantly, been We ancestry formed with just to Barstool not working this, and on He take Karkus He develop I've But an I'm et product. have incredible the expert. are DNA ancestry more that's offerings we test work of in research cetera. DNA Sports, is has Complete.
And marketing more be significantly an platform. media great lab all former cetera, et reports to Expand ancestry we test. year everybody, rolling better We Nebula. these this other data. with now thing the importantly, Complete. what special, excited mentioned DNA has this a Expand. new has not DNA as require going we who too about time much So had and we're does out.
And an building to advanced just Complete than
your test. you're ancestry from an ancestry.com, million consumers consumer, allowed you're All data. got MyHeritage, gotten XXandMe, XX if XX if download million, to you your So a ancestry have test
us. The $XX upload ancestry companies, the store You subscription All IT. $X.
Meanwhile, we us is can related other for data with you per is your some health-related us then then in provide year and XXandMe to might test. $X, to it only reports all, cost charging to the to have ancestry cost research to
reports. We after DNA you compared boosted We here, Users the We not can but your data health boost wellness it, more and I'm significantly has your test. data significantly going to science read it data. upload. to health-related into will more XXx more reports provide get behind expands DNA provide in-depth ancestry file significantly. typical
years, X don't that subscription So them information if be of generating like of do more provide we're more It's is. got a we $XX $XX could out a of But a $XX company, million, cost whatever We'll this $XX million business in $X.
This million? million, $XX $XX. get an million advertising not the minus -- $X and than a a I save enormous that out This everything know, one lot. million year the additional million, it for wealth million instead Throw revenue information. business. consumers of We'll just $XX providing or in million earning us in profits $XX focus is could $XX the to $XX year. cash $X on cow. would be cost $X the we
ramping So business. up I'm really looking forward to this
start do gifts. reason year this It's after giving the Christmas, now. capital want consumers advertising to Fridays, it's to holidays. want of time I start to Another is everyone Black go is now. we after want to them the I these going why raise, Best
Nebula about not I'm again, that. and on a spend excited products time these to lot of Think this launch.
And more Genomics, really moving laboratory. going as I'm our that So of forward
and also speak And on very field in Church, with world-renowned him board with him We've him having with for years supplements, a companies. of been We up we Harvard. advisory at George very working work it's regularly.
All closely genomics ProPhase pleasure quickly. on the real right. our these
When I to drug to the the and stores. XX,XXX Cold-EEZE As brand, we Legendz sold reach infrastructure mass a brand in wanted food, retail out we I mentioned, XL. have keep the to place
shipping, logistics. manufacturing, the have packaging, distribution, we So
was company of Brennan, senior control with us with We have when the I years investor. even over who's just been I took first I Joe more when remember the salesman, same our an than company. Joe being
expert and product he's retail into on company he I He's Expand XL worked Legendz the an So Cold-EEZE We're we million the do ProPhase in XX platform CVS launching this even $X.X very marketing media the million, and Walgreens.
We experts' XL a $X media is section, probably don't which cool. any advertising about stores. on that a the on then really going build also And we're been that's built on Complete into years. be selling DNA lead him in that. We're DNA with out year. placed it Legendz with. closely that and and just platform, around. turning supplements could to now whole
to We also which Triple complementary Legendz Edge, have XL. is
to that place. bundle You great workout was product. as the them can a keep But in together more importantly, more infrastructure
with same We now that the relationship the broker works to out we're in with relationships, country have roll sales with And retailers. going #X the Equivir. those great major the all
Equivir -- the a and sure not. say packaging I'm allowed to what on So is I'm what not I'm
What I so I'm I the the that studies rights we a large since the please, But not acquired all, you not about we very It's how ago. have tell we large out I very -- of product. So done But very a yet. independently be I that talk to did advertising of a were did can of -- first it. careful years time, before now few product study. clinical a lot ourselves
the Now patients. X see XX, would FDA of X-X, is to studies like at typically, what least
attorneys class off them, action all to least studies I many with, lawsuits also and avoid If class patients experience, action know no had you I but to XX from they Cold-EEZE. your this a want them. how I'd rather deal We back, with of want were at each. nuisance of you won the idea X keep you have nuisance
made sure launched launch I Equivir done. so I And that before until didn't it study want we -- this have was could clinical to we already.
X excited word back the wait all. we recently. that I've been in that talking result, my all can't really written final of the And the clinical should launch biggest we got a think on be product and up about be the XXX that for Equivir raw team final They results done the were that data patients. could is and to the results the I be and total before We'll is recently Equivir. initial to study So raw And of did researcher the phenomenal. arms, data preliminary year-end.
-- a of which of Now course, Esophageal businesses. from Cancer thing from could Equivir that's separate biggest the facility X mouth. reason from different believe take lozenge your I way, Cold-EEZE the still Cold-EEZE Cold-EEZE. And long is homeopathic view, and Test. are a sell. PMI, that manufacturing different be the a I that a for dissolves But is it's product by point there Those But our sits still BE-Smart in and time. It we in completely it.
buys products. don't like of Only and even people X% country Some it's about it the homeopathic. homeopathic taste the of
toot profitable. a fair that around it.
And what and myself. believe to details. I though not I of of when million. amount own to to manufacture very small a lozenge. small turned show but fair We want horn, amount and still still still it is brand market did $XX It around. Equivir in Cold-EEZE. did not is just I my was it I now grow and growing very doing not with to go sold brand I revenues. take doing I a That you, a business had I for homeopathic market. it turn it's and of a So had it a -- a and target into do it's small more fraction don't
out the the the go sell probably tested to cough/cold as The of been Equivir, you to. consumers except Cold-EEZE took sick either results sick, details we is season. have results meaning The I placebo. a now, we therapeutic, during X can arms. this many phenomenal. just as to half Xx of number sell that a that show more The you're cough, market preliminary that cold, you won't target turned -- is would as took the COVID. or market, if don't you Equivir probably preliminary for Xx that it took tell One included size market It flu days. the is results. And you many. if you was and So got into
getting itself. That's be We cough, the less we turned the be will compared said, a study. to but to COVID cold, able everything sick less every The will as I placebo. out therapeutic.
Then for take took Equivir from, prophylactic, group sick. it will of There you not incidences publish a claims, day, to that of taking flu, got results were make able COVID as the those meaning speak as
the So can't results. roll wait excited the this results -- really I'm about to I product. out
the than just I the our to now been I've never on talked Okay. future -- the of up have that given it's of it. stock I company price think more get trial important, especially I what's through with of developing. I and really bullish this, that. just highlights, we all am assets you clinical but people I right wrap on? like, going oh, the investment are timeline. I and all the And with about Equivir already want and The gone covered
not had years never in require never the that now have X, we of we've dollars. that sky and of pie millions assets assets these We get the have have potential the X maybe are we that in now. like it's tens commercialized wealth of had and And
So if what you tell, I'm about we can't enthusiastic have.
company. about say be can about lot expense. I future to that forward, where. to but I going I very have I'm that's to And going going financially, think I took in what you And going want do that's to me very a that making we for now, sure as of financials tell I'm ability and even financials, bright. very the and our a talk improve our very my significantly on what soon. don't I for have I what you make the sensitive the do largest shareholder is am as I our to to shareholder that's focus goal
is This XX for minutes. Usually, is you little now about your to XX presentation over a thank and my I time So XX. patience. your
know Noella, a there's -- -- questions out of there. sure there's I'm Let's I bunch
to an try and I'll try hour. -- Let's this and keep
Let's you over get Noella, we to questions, can. please. questions the to many as as for
